Theranostics

What is Nuclear Medicine Therapy or Theranostics

Nuclear Medicine Therapy, also called Peptide Receptor Radioligand Therapy (PRLT) is a form of targeted molecular treatment for cancers, that holds the ability to deliver high cytotoxicity to the targeted cancer cells. It is a specialised branch of Nuclear Medicine, also called Theranostics,  which combines diagnosis and therapy of tumors based on targeting of a receptor or antibody. Also nicknamed Precision Oncology, theranostics offers tailor-made treatment for every patient, to selectively target and kill only the cancer cells, while causing minimal damage to healthy organs and tissues in the body, thus producing very mild side effects.

Radioisotopes that emit beta and alpha particles like Lutetium 177, Yttrium 90, Actinium 225, and Lead 212 are used to selectively destroy cancer cells making use of their high but concentrated energy. Radionuclide therapy is a promising breakthrough in the treatment of cancers that have spread or metastasised -  commonly prostate cancer and neuroendocrine tumors, besides many others.

Who can benefit from Nuclear Medicine Therapy?

Radionuclide therapy is now clinically used for treating metastatic prostatic cancers and neuroendocrine tumors world over, with remarkable results. Clinical trials are underway for assessing their efficacy and possible use in more types of cancers. Prior chemotherapy, radiation therapy or radionuclide therapy (PRRT/PRLT) does not preclude the use of these therapies in suitable candidates.  It is available at few specialized molecular therapy centres worldwide. Available in India since over 10 years, PRLT is a very safe and effective and precise molecular targeted therapy for many cancers. 

To know more please contact us. theranosticsindia@gmail.com